BPH-Related Voiding Dysfunction—i-Tind

  • Dominique Guelce
  • Mitlai Kini
  • Dominique Thomas
  • Bilal ChughtaiEmail author
BPH-Related Voiding Dysfunction (R Lee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on BPH-Related Voiding Dysfunction
  2. Topical Collection on BPH-Related Voiding Dysfunction


Purpose of Review

Benign prostatic hyperplasia (BPH) is a common condition that affects a majority of the aging male population. The majority of aging male population was afflicted with lower urinary tract symptoms (LUTS). Over the past several years, there has been an armamentarium of advances in the treatment of this condition to improve a patient’s quality of life (QoL). A new treatment that shows promising results is the i-TIND system, an implantable device.

Recent Findings

We present the most current literature on this therapy. There are ongoing trials evaluating the use of the newer second-generation i-Tind, although there are currently no functional differences from the first-generation device. The pilot study of the first-generation device was shown to improve both IPSS score and Qmax over the course of 12 months with a trend to benefit in the 24 to 36-month period. The i-Tind represents another attempt to introduce an office-based procedure for the treatment of BPH. The preliminary results seem to indicate that this device shows efficacy in improving urinary symptoms.


There is promising evidence for the use of i-Tind as an office-based treatment for BPH. An important consideration, however, will center on patient selection. There will be a cohort of men who elect to undergo this minimally invasive procedure over the gold standard TURP. However, this will not be a viable treatment option for men with particularly large prostate volumes.




Compliance with Ethical Standards

Conflict of Interest

Dominique Guelce declares that he has no conflict of interest.

Mitali Kini declares that she has no conflict of interest.

Dominique Thomas declares that she has no conflict of interest.

Bilal Chughtai declares that he is an investigator for Medi-Tate, Astellas, and Ipsen. He is also a speaker for Boston Scientific.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    •• Porpiglia F, et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278–87 First study evaluating the intermediate follow-up of the i-TIND device.CrossRefGoogle Scholar
  2. 2.
    •• Porpiglia F, et al. 3-year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018;122(1):106–12 Offered 3-years follow-up of the durability of i-TIND device. Showed device was able to improve urinary symptoms such as Qmax as well as IPSS and QoL.CrossRefGoogle Scholar
  3. 3.
    Bertolo R, Fiori C, Amparore D, Porpiglia F. Follow-up of temporary implantable nitinol device (TIND) implantation for the treatment of BPH: a systematic review. Curr Urol Rep. 2018;19(6):44.CrossRefGoogle Scholar
  4. 4.
    Shulman FP, et al. PD27-03 the new MediTate® temporary implantable nitinol device (I-TIND) in the treatment of bladder outlet obstruction due to BPH: results of one arm, multi-center prospective, study. J Urol. 2017;197(4).Google Scholar
  5. 5.
    Marcon J, Magistro G, Stief CG, Grimm T. What’s new in TIND? Eur Urol Focus. 2018;4(1):40–2.CrossRefGoogle Scholar
  6. 6.
    •• Porpiglia F, et al. Second-generation of temporary implantable nitinol device (i-TIND) for the relief of lower urinary tract symptoms due to BPH: results of a prospective, multi-center study at 1 year of follow-up. BJU Int. 2018; First study published detailing the effectiveness of the second generation i-TIND device.Google Scholar
  7. 7.
    Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Dominique Guelce
    • 1
  • Mitlai Kini
    • 1
  • Dominique Thomas
    • 1
  • Bilal Chughtai
    • 1
    • 2
    Email author
  1. 1.Department of UrologyWeill Cornell Medical College New York-PresbyterianNew YorkUSA
  2. 2.Department of Obstetrics and GynecologyWeill Cornell MedicineNew YorkUSA

Personalised recommendations